Western Regional Blog – BC, YK, AB, NWT and Nunavut
“This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.”
Review Article | April 15, 2013 |
By J. Alejandro Rauh-Hain, MD and Marcela G. Del Carmen, MD, MPH
ABSTRACT: An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.
An estimated 75% of women with ovarian cancer present with advanced-stage (III or IV) disease. For patients with low residual disease (all lesions < 1 cm in size following surgical debulking), the risk for recurrence after completion of primary therapy is 60% to 70%; however, for women with large-volume residual disease, the risk is estimated at 80% to 85%.
We conducted a systematic review using the MEDLINE database, PubMed, EMBASE, and the Cochrane Library. The search was restricted to English-language articles published from 1979 through July 2012.
Priority was given to articles reporting original research, in particular randomized controlled trials, although review articles and commentaries also were consulted. Recent abstracts of research presented at symposia and scientific conferences were also considered. *…}
Role of Timing in the Treatment of Recurrent Ovarian Cancer
Recurrent ovarian cancer can be heralded by onset of new symptoms, radiologic evidence of recurrent disease, or a rising CA-125 level in an asymptomatic patient. CA-125 elevation may precede radiologic detection or onset of symptoms by several months.[6,7] Although formal definitions of ovarian cancer recurrence and progression have been described, based on both clinical and CA-125 criteria, many patients present with either an asymptomatic, radiologic recurrence or an asymptomatic rise in CA-125 level without a radiographic correlate.[7,8] *…+
See more at: http://www.cancernetwork.com/review-articles/recurrent-epithelial-ovarian-cancer-update-treatment/page/0/1?GUID=5029A80D-00ED-416D-88C6-349784B6C0C9&rememberme=1&ts=26122013#sthash.pZQkcPZ3.dpuf